Back to search results

Understanding Long-Term Lung Problems After COVID-19

This study aims to understand why some people have lasting lung problems like shortness of breath and tiredness after a severe COVID-19 infection. Researchers will use various tests including Bronchoscopies and Bronchoalveolar Lavages (BALs) (a procedure using a thin tube to look at your lungs and collect samples), Chest Tomography (CT) scans (X-rays for internal organs), Electrocardiograms (ECG) (measures heart activity), Pulmonary function tests (PFTs) (measures lung function), and a 6-minute walk test. You may be able to join if you are 18 or older, had COVID-19 confirmed by a PCR test, were hospitalized for COVID-19, and do not have pre-existing lung disease. The study will look for clinical, imaging, immune, molecular, and/or viral traits that explain these long-term lung issues, with results expected after 4 years. The current recruitment status is unclear.

Study design
This is an observational study with a planned enrollment of 67 participants. It is not specified if it is randomized or blinded.
What's involved
You would be in the study for about 12 months, with 3 visits to Mayo Clinic. These visits occur around 2-3 months, 6 months, and 12 months after your COVID-19 diagnosis.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 4 years to assess clinical, imaging, immune, molecular, and/or viral traits.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06006884

A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae

Recruiting
Not specifiedAges 18+Observational
Mayo Clinic
~67 participants
Updated 2026-05-07 on ClinicalTrials.gov
What's tested:Bronchoscopies and Bronchoalveolar Lavages (BALs)Chest Tomography (CT)Electrocardiogram (ECG)Pulmonary function tests (PFTs)6 minute walk test (6MWT)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Decipher clinical, imaging, immune, molecular and/or viral traits underlying post-acute COVID-19 lung sequelae
Measured over 4 years

Conditions

COVID-19

Explore related trials

COVID-19 InfectionPost-Acute Sequelae of COVID-19

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Robert Vassallo, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Chris Roberts
[email protected]
800-753-1606
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years at screening, PCR confirmed COVID19 illness (+PCR defines day 0 of illness), hospitalization for COVID-19, absence of pre-existing history of interstitial lung disease, or significant other lung disease.
Severity of illness will be categorized as moderate disease (supplemental oxygen need 1-8L at any time during hospitalization), severe disease (need for high flow oxygen delivery ≥8L at any time during hospitalization) and critical illness (need for ICU admission or mechanical ventilation).
Age ≥18 years at screening
PCR confirmed COVID-19 cases who had nonsymptomatic or mild acute infection that do not require hospitalization 7,48,49
Absence of pre-existing history of interstitial lung disease, or significant other lung disease, absence of any ongoing respiratory and systemic symptoms.

Exclusion

Inability to provide informed consent, evidence of pre-existing interstitial lung disease or chronic lung disease;
Active cigarette smoking, vaping or other inhalation use.
Immunocompromised host status due to ongoing therapy with methotrexate, CellCept, azathioprine, rituximab, cyclophosphamide or other biologic agents;
\> 20 pack year smoking history.
History of chemotherapy or radiation therapy in the last two years; and pregnancy.

What this trial measures

  • Decipher clinical, imaging, immune, molecular and/or viral traits underlying post-acute COVID-19 lung sequelae4 years

    This study will expand on prior observations from a previous study and discover potential drivers and targets for therapy of post-acute COVID-19 lung disease by recruiting a larger group of COVID-19 convalescents, following up longitudinally up to 12 months after acute infection. This longitudinal approach will allow for assess immune dysregulation and establish the etiology of lung sequelae of COVID-19